MedTrace Logo

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2026-05-11

No results posted yet for this study

Summary

Obesity is considered a global pandemic and is associated with various diseases and metabolic complications, such as type 2 diabetes mellitus, high blood pressure, cholesterol disorders, cancer, cardiovascular disease, and kidney disease. Obesity can affect the kidneys in two main ways: indirectly, through mechanisms related to diabetes mellitus and/or high blood pressure, and directly, through complex proteins called "adipokines," which are produced by adipocytes.

Many of these adipokines are secreted by adipocytes under normal conditions, as they contribute to maintaining immune defenses and energy production. However, in obesity these adipokines acquire harmful properties and produce chronic inflammation in vital organs, such as the heart, blood vessels, the pancreas, and the kidney, leading to a deterioration in liver and kidney function.

New drugs such as glucagon-like peptide-1 receptor agonists (GLP-1Ras / Semaglutide), are not only effective to regulate blood sugar levels, but they produce weight loss improving kidney and liver function. However, little is known about their specific effect on the adipose tissue. Therefore, studies focusing on how these drugs work in fat could help us understand how diseased adipose tissue can affect patients with heart, liver, and kidney disease.

Investigators are asking patients who attend the diabetes clinics associated with the University of Alberta to join the study.

Conditions

  • Chronic Kidney Disease in Type 2 Diabetes
  • Obesity & Overweight

Sponsors & Collaborators

  • Novo Nordisk Canada Inc.

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Paolo Raggi, M.D · University of Alberta

  • Luis G D'Marco, M.D; Ph,D. · CEU Cardenal Herrera University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-23
Primary Completion
2027-12-15
Completion
2028-01-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187830 on ClinicalTrials.gov